ksn.com

inmind .ai Expands Presence to the USA, Delivering Creative and Innovative AI Solutions to Empower Businesses in the Era of Digital Transformation

GREENVILLE S.C., June 7, 2023 /PRNewswire/ -- inmind .ai, a multi-disciplinary software company and provider of AI solutions, among other services, is delighted to announce its expansion to the USA, ...
Yahoo Finance

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory ...

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first ...
Business Insider

Incyte, MorphoSys Say First Patient Dosed In Phase 3 InMIND Study On Follicular Lymphoma

(RTTNews) - Incyte (INCY) and MorphoSys AG (MOR) said that the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo ...
Pharm Exec

FDA Approves Incyte’s Monjuvi for Relapsed or Refractory Follicular Lymphoma

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in patients treated ...